Should I buy or sell Assertio stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Assertio in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ASRT shares. View ASRT analyst ratings or view top-rated stocks .

What is Assertio's stock price target for 2024?

1 Wall Street research analysts have issued 12 month price objectives for Assertio's shares. Their ASRT share price targets range from $4.00 to $7.00. On average, they anticipate the company's share price to reach $5.50 in the next year. This suggests a possible upside of 605.0% from the stock's current price. View analysts price targets for ASRT or view top-rated stocks among Wall Street analysts .

How have ASRT shares performed in 2024?

Assertio's stock was trading at $1.07 at the beginning of 2024. Since then, ASRT shares have decreased by 27.1% and is now trading at $0.7801. View the best growth stocks for 2024 here .

When is Assertio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our ASRT earnings forecast .

How were Assertio's earnings last quarter?

Assertio Holdings, Inc. (NASDAQ:ASRT) released its quarterly earnings results on Monday, March, 11th. The company reported $0.08 earnings per share for the quarter. The company had revenue of $32.99 million for the quarter, compared to analyst estimates of $31.42 million. Assertio had a positive trailing twelve-month return on equity of 6.30% and a negative net margin of 218.28%.

What guidance has Assertio issued on next quarter's earnings?

Assertio issued an update on its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $110.0 million-$125.0 million, compared to the consensus revenue estimate of $160.6 million.

What other stocks do shareholders of Assertio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Assertio investors own include Sorrento Therapeutics (SRNE) , Actinium Pharmaceuticals (ATNM) , T2 Biosystems (TTOO) , VBI Vaccines (VBIV) , InterDigital (IDCC) , Trevena (TRVN) , Bionano Genomics (BNGO) , Cerecor (CERC) and OPKO Health (OPK) .

Who are Assertio's major shareholders?

Assertio's stock is owned by many different retail and institutional investors. Top institutional investors include Denali Advisors LLC (0.17%). Insiders that own company stock include Ajay Patel , Daniel A Peisert , Heather L Mason, James L Tyree, Paul Schwichtenberg , Sam Schlessinger and William Mckee. View institutional ownership trends .

How do I buy shares of Assertio?

Shares of ASRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ASRT

Assertio (ASRT) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free ASRT Stock Alerts

$0.76

+0.01 (+0.93%)

(As of 03:58 PM ET)

Compare

Today's Range: $0.75
▼
$0.80
50-Day Range: $0.78
▼
$1.14
52-Week Range: $0.75
▼
$8.01

Volume: 804,628 shs
Average Volume: 1.02 million shs
Market Capitalization: $72.30 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.50

Get Assertio alerts:

Assertio MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 605.0% Upside
$5.50 Price Target
Short Interest: Bearish
10.93% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$11,481 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.04) to $0.19 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.19 out of 5 stars

Medical Sector

759th out of 918 stocks

Pharmaceutical Preparations Industry

343rd out of 419 stocks

3.5

Analyst's Opinion

Consensus Rating
Assertio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Assertio has received no research coverage in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
10.93% of the outstanding shares of Assertio have been sold short.
Short Interest Ratio / Days to Cover
Assertio has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.
Change versus previous month
Short interest in Assertio has recently decreased by 3.26%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Assertio does not currently pay a dividend.
Dividend Growth
Assertio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ASRT.

0.0

News and Social Media Coverage

Search Interest
Only 8 people have searched for ASRT on MarketBeat in the last 30 days. This is a decrease of -58% compared to the previous 30 days.
MarketBeat Follows
Only 5 people have added Assertio to their MarketBeat watchlist in the last 30 days. This is a decrease of -55% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Assertio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,481.00 in company stock.
Percentage Held by Insiders
Only 7.90% of the stock of Assertio is held by insiders.
Percentage Held by Institutions
48.96% of the stock of Assertio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Assertio are expected to grow in the coming year, from ($0.04) to $0.19 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Assertio is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Assertio is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Assertio has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Assertio Stock (NASDAQ:ASRT)

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

ASRT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ASRT Stock News Headlines

April 3, 2024 | finance.yahoo.com

Sig Kirk Joins Assertio Board of Directors

April 1, 2024 | globenewswire.com

Assertio to Present at LD Micro Invitational Conference in New York City

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

March 14, 2024 | finance.yahoo.com

These Analysts Think Assertio Holdings, Inc.'s (NASDAQ:ASRT) Earnings Are Under Threat

March 12, 2024 | finance.yahoo.com

Assertio Holdings Inc (ASRT) Reports Mixed Fourth Quarter and Full Year 2023 Financial Results

March 12, 2024 | finanznachrichten.de

Assertio Holdings, Inc.: Assertio Reports Fourth Quarter and Full Year 2023 Financial Results

March 12, 2024 | finance.yahoo.com

Q4 2023 Assertio Holdings Inc Earnings Call

March 12, 2024 | insidermonkey.com

Assertio Holdings, Inc. (NASDAQ:ASRT) Q4 2023 Earnings Call Transcript

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

March 11, 2024 | benzinga.com

Recap: Assertio Holdings Q4 Earnings

March 11, 2024 | msn.com

Assertio Holdings Non-GAAP EPS of $0.11, revenue of $32.99M misses by $0.82M

March 11, 2024 | sfgate.com

Assertio: Q4 Earnings Snapshot

March 11, 2024 | globenewswire.com

Assertio Reports Fourth Quarter and Full Year 2023 Financial Results

March 11, 2024 | msn.com

Sam Altman retorna ao conselho da OpenAI; Coinbase, MicroStrategy sobem no pré-mercado com novo marco do BTC, e mais

March 11, 2024 | finance.yahoo.com

ASRT Mar 2024 4.500 call

March 10, 2024 | msn.com

Assertio Holdings Q4 2023 Earnings Preview

March 8, 2024 | benzinga.com

Assertio Holdings's Earnings: A Preview

March 5, 2024 | prnewswire.com

The Gross Law Firm Notifies Assertio Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ASRT

March 4, 2024 | stockhouse.com

Assertio 24 Hour Deadline Alert

March 4, 2024 | businesswire.com

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Assertio Holdings, Inc. (ASRT)

March 3, 2024 | markets.businessinsider.com

Assertio 48 Hour Deadline Alert

March 3, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Assertio Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines - ASRT

March 1, 2024 | stockhouse.com

Assertio Shareholder Notice

February 29, 2024 | finance.yahoo.com

Assertio Holdings, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024

February 29, 2024 | globenewswire.com

Assertio Holdings, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024

February 29, 2024 | prnewswire.com

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Assertio

February 28, 2024 | prnewswire.com

Kessler Topaz Meltzer & Check, LLP Reminds Assertio Holdings, Inc. (ASRT) Investors of March 5, 2024 Lead Plaintiff Deadline and Urges Investors with Substantial Losses to Contact the Firm

See More Headlines

Receive ASRT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Assertio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/11/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ASRT
CUSIP: N/A
CIK: 1808665
Web: www.assertiotx.com
Phone: (224) 419-7106
Fax: 510-744-8001
Employees: 53
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.50
High Stock Price Target: $7.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +605.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.97)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-331,940,000.00
Net Margins: -218.28%
Pretax Margin: -167.07%
Return on Equity: 6.30%
Return on Assets: 3.54%

Debt

Debt-to-Equity Ratio: 0.28
Current Ratio: 1.83
Quick Ratio: 1.43

Sales & Book Value

Annual Sales: $152.07 million
Price / Sales: 0.49
Cash Flow: $0.73 per share
Price / Cash Flow: 1.07
Book Value: $1.46 per share
Price / Book: 0.53

Miscellaneous

Outstanding Shares: 95,000,000
Free Float: 87,495,000
Market Cap: $74.11 million
Optionable: Optionable
Beta: 0.96

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Ms. Heather L. Mason (Age 64)
Interim CEO & Director
Comp: $92.5k
Mr. Ajay Patel (Age 39)
Senior VP & CFO
Comp: $742.01k
Mr. Paul Schwichtenberg (Age 52)
Senior Vice President & Chief Commercial Officer
Comp: $780.88k
Mr. Bill Iskos
Senior Vice President of Operations
Ms. Molly Dir
Senior Vice President of HR & Administration ?
Mr. Sam Schlessinger
Senior VP & General Counsel
Dr. Howard J. Franklin M.B.A.
M.D., Senior Vice President of Medical

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ASRT Stock Analysis - Frequently Asked Questions

Should I buy or sell Assertio stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Assertio in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ASRT shares.
View ASRT analyst ratings or view top-rated stocks.
What is Assertio's stock price target for 2024?: 1 Wall Street research analysts have issued 12 month price objectives for Assertio's shares. Their ASRT share price targets range from $4.00 to $7.00. On average, they anticipate the company's share price to reach $5.50 in the next year. This suggests a possible upside of 605.0% from the stock's current price.
View analysts price targets for ASRT or view top-rated stocks among Wall Street analysts.
How have ASRT shares performed in 2024?: Assertio's stock was trading at $1.07 at the beginning of 2024. Since then, ASRT shares have decreased by 27.1% and is now trading at $0.7801.
View the best growth stocks for 2024 here.
When is Assertio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our ASRT earnings forecast.
How were Assertio's earnings last quarter?: Assertio Holdings, Inc. (NASDAQ:ASRT) released its quarterly earnings results on Monday, March, 11th. The company reported $0.08 earnings per share for the quarter. The company had revenue of $32.99 million for the quarter, compared to analyst estimates of $31.42 million. Assertio had a positive trailing twelve-month return on equity of 6.30% and a negative net margin of 218.28%.

What guidance has Assertio issued on next quarter's earnings?: Assertio issued an update on its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $110.0 million-$125.0 million, compared to the consensus revenue estimate of $160.6 million.
What other stocks do shareholders of Assertio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Assertio investors own include Sorrento Therapeutics (SRNE), Actinium Pharmaceuticals (ATNM), T2 Biosystems (TTOO), VBI Vaccines (VBIV), InterDigital (IDCC), Trevena (TRVN), Bionano Genomics (BNGO), Cerecor (CERC) and OPKO Health (OPK).
Who are Assertio's major shareholders?: Assertio's stock is owned by many different retail and institutional investors. Top institutional investors include Denali Advisors LLC (0.17%). Insiders that own company stock include Ajay Patel, Daniel A Peisert, Heather L Mason, James L Tyree, Paul Schwichtenberg, Sam Schlessinger and William Mckee.
View institutional ownership trends.
How do I buy shares of Assertio?: Shares of ASRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ASRT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Assertio (ASRT) Stock Price, News & Analysis

Assertio MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Assertio Stock (NASDAQ:ASRT)

ASRT Stock Price History

ASRT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ASRT Stock Analysis - Frequently Asked Questions

Overall MarketRank^™